Revolution Medicines, Inc. (RVMD)
| Market Cap | 2.96B |
| Revenue (ttm) | 42.98M |
| Net Income (ttm) | -110.38M |
| Shares Out | 54.87M |
| EPS (ttm) | -21.25 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 19 |
| Last Price | $38.74 |
| Previous Close | $40.32 |
| Change ($) | -1.58 |
| Change (%) | -3.92% |
| Day's Open | 39.93 |
| Day's Range | 38.74 - 40.71 |
| Day's Volume | 66,456 |
| 52-Week Range | 21.17 - 56.18 |
Revolution Medicines' leading compound is shaping up to be a platform in a pill.
Presentations Highlight Continued Progress Across Expanded R&D Pipeline of RAS(ON) Inhibitors and RAS Companion Inhibitors Presentations Highlight Continued Progress Across Expanded R&D Pipeline of RAS(...
REDWOOD CITY, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets ...
Advanced and Expanded Portfolio of RAS(ON) Inhibitors; Two Assets Entered IND-Enabling Development
Steve Kelsey, M.D., President, Research and Development, to Present its Pioneering RAS(ON) Inhibitors and Participate in Panel Discussion Steve Kelsey, M.D., President, Research and Development, to Pres...
Underwriters' Full Exercise of Option Brings Gross Proceeds to $300 Million
REDWOOD CITY, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD) today announced the pricing of its underwritten public offering of 5,797,101 shares of common stock at a...
REDWOOD CITY, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD) today announced that it has commenced an underwritten public offering of 4,000,000 shares of common stoc...
REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets i...
Revolution Medicines (NASDAQ: RVMD) shares are trading higher on Thursday after the company reported a third-quarter EPS loss of 42 cents, up from a loss of $6.08 year-over-year and sales $12.66 million...
Recommended Phase 2 Dose and Schedule Selected for Further Evaluation of RMC-4630 as Monotherapy and RMC-4630 plus Cobimetinib Combination
Plenary Presentation at EORTC-NCI-AACR 3 2 nd Symposium on Molecular Targets and Cancer Therapeutics Describes Encouraging Tolerability and Exposure Profile s for RMC-4630 Combined with Cobimetinib and ...
Study Findings Selected for Oral Presentation in Plenary Session at EORTC-NCI-AACR 32nd Symposium on Molecular Targets and Cancer Therapeutics Study Findings Selected for Oral Presentation in Plenary Se...
Revolution Medicines (RVMD) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Presentation at 2nd Annual RAS-Targeted Drug Development Conference Highlights First Publicly Reported Data for Inhibitors of Notorious Cancer Protein KRASG12D(ON)
REDWOOD CITY, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit fron...
Company’s Scientific Leadership to Deliver Presentations, Participate in Panel Discussion and Co-Lead Workshop During Digital Event Company’s Scientific Leadership to Deliver Presentations, Participate ...
Interim RMC-4630 Data Support Benefit of Intermittent Dosing and Corroborate Clinical Activity Against Genetically-Defined Tumors
Underwriters’ Full Exercise of Option Brings Gross Proceeds to $179.4 Million Underwriters’ Full Exercise of Option Brings Gross Proceeds to $179.4 Million
Revolution Medicines (RVMD) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
REDWOOD CITY, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD) today announced the pricing of its underwritten public offering of 6,000,000 shares of common stock at ...
REDWOOD CITY, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD) today announced that it has commenced an underwritten public offering of 5,500,000 shares of common sto...
Newly Discovered Natural Product and Designed Analogues Bind to Human Protein that is Exploited by the SARS-CoV-2 Virus Newly Discovered Natural Product and Designed Analogues Bind to Human Protein that...
REDWOOD CITY, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer...
Combination of Investigational SHP2 Inhibitor and Anti-PD-1 Antibody to be Evaluated in Patients with Solid Tumors Combination of Investigational SHP2 Inhibitor and Anti-PD-1 Antibody to be Evaluated in...
REDWOOD CITY, Calif., June 18, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer...
Study Evaluates Combination Treatment with Investigational SHP2 and KRASG12C Inhibitors in Patients with KRASG12C Mutant Solid Tumors
Company to Host R&D Update Conference Call Following AACR Meeting Company to Host R&D Update Conference Call Following AACR Meeting
Closed Initial Public Offering Raising Gross Proceeds of $273.7 Million
Findings Support Plans to Expand Clinical Evaluation of RMC-4630, the Company’s Investigational SHP2 Inhibitor, to Include Combination with Anti-PD-1 Drug Findings Support Plans to Expand Clinical Evalu...
Multi-cohort Phase 1/2 Clinical Program Currently Evaluating RMC-4630 Multi-cohort Phase 1/2 Clinical Program Currently Evaluating RMC-4630
Netherlands Cancer Institute Intends to Sponsor and Conduct Phase 1/1b SHERPA Trial in Patients with Tumors Harboring RAS Mutations Netherlands Cancer Institute Intends to Sponsor and Conduct Phase 1/1b...
Revolution Should Be On Your Radar; 'Undruggable Targets' Now Potentially Druggable
Shares of cancer-specialist Revolution Medicines soared on its first day of public trading.
The share price of a clinical-stage oncology company that went public just last week has climbed more than 70% on hopes that it can develop drugs to transform the way cancer is treated.
REDWOOD CITY, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontie...
Revolution Medicines Inc. (NASDAQ: RVMD) entered the market with a bang on Thursday.
Shares of Revolution Medicines Inc. , a clinical-stage oncology company, soared 85% Thursday in their trading debut, after underwriters priced the initial public offering at the top end of a revised range.
About RVMD
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the... [Read more...]
| Industry Biotechnology | IPO Date Feb 13, 2020 |
| CEO Mark Goldsmith | Employees 125 |
| Stock Exchange NASDAQ | Ticker Symbol RVMD |
Financial Performance
In 2020, RVMD's revenue was $42.98 million, a decrease of -14.10% compared to the previous year's $50.04 million. Losses were -$108.16 million, 126.9% more than in 2019.
Analyst Forecasts
According to 5 analysts, the average rating for RVMD stock is "Buy." The 12-month stock price forecast is 54.00, which is an increase of 39.39% from the latest price.